
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is projected to experience significant growth in its financial performance, with EBITDA expected to rise from $22.1 million in FY26, reflecting a margin of 16.8%, to $27.3 million in FY27, which indicates an improved margin of 19.1%. Furthermore, the company has turned positive in free cash flow, projecting $5.1 million in FY26 and an increase to $6.0 million in FY27. These trends in both profitability and cash flow generation provide a robust foundation for a favorable outlook on Lifecore Biomedical's stock performance.
Bears say
Lifecore Biomedical is projected to experience a market growth that may be slightly below the anticipated 10% for fill/finish services, raising concerns about its ability to capitalize on industry trends. The company's high leverage ratio further exacerbates these concerns, as it indicates a heavier debt burden relative to its earnings potential. Additionally, significant revenue growth is not expected until calendar year 2027, which negatively impacts the company’s financial outlook compared to its peers.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares